Last reviewed · How we verify

buprenorphine / methadone sequence — Competitive Intelligence Brief

buprenorphine / methadone sequence (buprenorphine / methadone sequence) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist substitution therapy. Area: Addiction Medicine / Substance Use Disorder.

marketed Opioid agonist substitution therapy Mu-opioid receptor (μ-OR) Addiction Medicine / Substance Use Disorder Small molecule Live · refreshed every 30 min

Target snapshot

buprenorphine / methadone sequence (buprenorphine / methadone sequence) — Karolinska University Hospital. A sequential treatment protocol using buprenorphine followed by methadone, both opioid agonists that bind to mu-opioid receptors to reduce withdrawal symptoms and cravings in opioid use disorder.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
buprenorphine / methadone sequence TARGET buprenorphine / methadone sequence Karolinska University Hospital marketed Opioid agonist substitution therapy Mu-opioid receptor (μ-OR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist substitution therapy class)

  1. Karolinska University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). buprenorphine / methadone sequence — Competitive Intelligence Brief. https://druglandscape.com/ci/buprenorphine-methadone-sequence. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: